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OBJECTIVE — To evaluate whether treatment with insulin is advantageous compared with
oral antidiabetes agents in newly diagnosed type 2 diabetes with severe hyperglycemia after
short-term intensive insulin therapy.
RESEARCH DESIGN AND METHODS — Newly diagnosed type 2 diabetic patients
with severe hyperglycemia were hospitalized and treated with intensive insulin injections for
10–14 days. The oral glucose tolerance test (OGTT) was performed after intensive insulin
treatment. After discharge, the patients were randomized to receive either insulin injections or
oralantidiabetesdrugs(OADs)forfurthermanagement.TheOGTTwasrepeated6monthslater,
and-cellfunctionandinsulinsensitivitywereevaluatedagain.Thesesubjectswerecontinually
followed up for another 6 months to evaluate their long-term glycemic control.
RESULTS — Atthe6thmonthofthestudy,theA1Clevelwassigniﬁcantlylowerintheinsulin
group than in the OAD group (6.33  0.70% vs. 7.50  1.50%; P  0.002). During the
follow-up visit, the A1C level was still better in the insulin group (6.78  1.21% vs. 7.84 
1.74%; P  0.009). All parameters regarding -cell function measured in the OGTT were
improved signiﬁcantly in both groups after 6 months of treatment. Compared with the OAD
group, the homeostasis model assessment of -cell function index, insulin area under the curve,
and insulinogenic index were better in the insulin group.
CONCLUSIONS — A 6-month course of insulin therapy, compared with OAD treatment,
could more effectively achieve adequate glycemic control and signiﬁcant improvement of -cell
function in new-onset type 2 diabetic patients with severe hyperglycemia.
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I
nsulin resistance and impaired insulin
secretion are the main pathophysiologi-
cal defects responsible for the develop-
ment of hyperglycemia in type 2 diabetes
(1,2). With the continuous presence of in-
sulin resistance, progressive loss of -cell
function is the crucial defect. The continu-
ous decline in -cell function is affected by
glucotoxicity generated by hyperglycemia
and lipotoxicity due to lipolysis (3). Im-
paired -cell function appears to be revers-
ible, particularly in the early stage of the
disease, when the limiting threshold for re-
versibility of decreased -cell mass has
probablynotbeenpassed(4).Sothepoten-
tialbeneﬁtsofearly,aggressiveintervention
with insulin treatment to counter both
-cell dysfunction and insulin resistance
must be considered. Several reports (5–7)
have shown that short-term intensive insu-
lin therapy can induce long-term glycemic
control in newly diagnosed type 2 diabetic
patients with mild to moderate hyperglyce-
mia. However, more than half of these pa-
tients require oral antidiabetes drug (OAD)
therapy within 1 year to maintain near-
euglycemia.
When a new-onset type 2 diabetic pa-
tient presents with severe hyperglycemia,
therearedefectsininsulinsecretionandac-
tion,whichisoptimallytreatedwithaggres-
sive insulin injections (8,9). After the
symptoms have been relieved, it may be
possible to withdraw insulin and shift to
oral agents. We hypothesized that continu-
ous insulin therapy for a few months in
new-onset type 2 diabetes with severe hy-
perglycemia may have a prolonged glyce-
mic control. To address this concept, we
designed this 6-month study to evaluate
whether treatment with insulin is advanta-
geous compared with OADs in newly diag-
nosed type 2 diabetes with severe
hyperglycemia after short-term intensive
insulin therapy.
RESEARCH DESIGN AND
METHODS— Consecutive newly di-
agnosed type 2 diabetic patients with se-
vere hyperglycemia (fasting plasma
glucose [FPG] 300 mg/dl or random
plasma glucose 400 mg/dl) were re-
cruited between October 2005 and De-
cember 2006. All patients were admitted
to the hospital and received intensive in-
sulin therapy. The excluding criteria in-
cluded active liver disease, serum
creatinineconcentration2.0mg/dlafter
5–10 days of therapy, proliferative dia-
beticretinopathy,deﬁnitecoronaryartery
disease, malignancy, and pregnancy. The
patients with peak C-peptide levels dur-
ingtheoralglucosetolerancetest(OGTT)
2.0ng/mlwerealsoexcludedtoruleout
type 1 diabetes and latent autoimmune
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proved by the institutional review board
of the Taipei Veterans General Hospital,
and written informed consent was given
before the OGTT.
During the hospitalization
The basal and premeal insulin doses were
adjustedaccordingtothepreprandialand
bedtime capillary blood glucose levels.
Thetargetglucoselevelswerepreprandial
blood glucose 90–130 mg/dl and bed-
time blood glucose 100–160 mg/dl. After
10–14 days of intensive insulin treat-
ment,withtheirfastingbloodglucoselev-
els between 100 and 140 mg/dl, subjects
receiveda75-gOGTTafterdiscontinuing
regular insulin for 12 h and NPH insu-
linforabout24h.Baselinebloodsamples
were drawn for A1C, cholesterol, triglyc-
erides, glucose, insulin, C-peptide, and
other biochemicals. Blood samples were
furthercollectedforglucoseandinsulinat
30, 60, 90, and 120 min and C-peptide at
120 min.
Outpatient clinic follow-up
All subjects were discharged after 10–14
daysofintensiveinsulintherapyandthen
randomized into two groups: continuing
with insulin treatment or shifting to
OADs. Subjects were then followed up as
outpatients and visited our clinic every 2
weeks during the ﬁrst 2 months and then
every 4 weeks for another 4 months.
In the insulin therapy group, subjects
wereinstructedinthetechniquesforNPH
insulin (Insulatard; Novo Nordisk, Bags-
værd, Denmark) injection and home cap-
illary glucose monitoring. Two-thirds of
the daily dose was administrated before
breakfastandtheotherwasadministrated
atbedtime.Insulindosesweretitratedev-
ery 3 days to achieve target FPG values
between 90 and 130 mg/dl.
The titration of OADs in our protocol
was modiﬁed from the Steno-2 Study
publishedin2003(10).Astheinitialstep,
overweight or obese patients (deﬁned as
BMI 25 kg/m
2) received metformin
(submaximal dose 500 mg t.i.d.) and lean
patients received a sulfonylurea (glicla-
zide-MR, submaximal dose 90 mg per
day).Thedosagewastitratedbasedonthe
FPG on the visiting day to achieve target
values between 90 and 130 mg/dl. As the
second step, metformin was given to the
lean patients and gliclazide-MR to over-
weight or obese patients. As the third
step, gliclazide-MR should be uptitrated
to a maximum dose of 120 mg per day
and metformin to 2,550 mg per day with
a splitting dose.
Clinical examination
A1C measurements were further per-
formed at 3 and 6 months, and the OGTT
was repeated after 6 months of random-
ization. We stopped pharmacological
treatment for 12 h (metformin after the
evening dose) and 24 h (gliclazide-MR
andinsulatardafterthemorningdose)be-
fore performing the OGTT. Area under
the curve (AUC) for glucose and insulin
during the OGTT were calculated by the
trapezoid rule. Early-phase insulin secre-
tion (insulinogenic index) was calculated
as the ratio between incremental plasma
insulin and glucose concentrations dur-
ing the ﬁrst 30 min of the OGTT (I0–30/
G0–30). Total insulin secretion was cal-
culated as the ratio between the incre-
mentalAUCofinsulinandglucoseduring
the OGTT (I[AUC]/G[AUC]). The
Matsuda index was calculated for insu-
lin resistance, as previously reported
(11). Homeostasis model assessment
(HOMA) was used to estimate insulin re-
sistance (HOMA-IR) and -cell function
(HOMA-) (12).
Follow-up examination
After6monthsofintervention,patientsin
the insulin group also shifted to OADs for
further management. All of these subjects
were continually followed up in our clin-
ics for another 6 months to evaluate their
long-term glycemic control.
Analytical methods
Plasmainsulinlevelswereassayedusingdi-
rect chemiluminescent technology with a
two-site sandwich immunoassay (ADVIA
Centaur; Bayer, Tokyo, Japan). The A1C
was measured using high-performance liq-
uid chromatography instruments (HLC-
723 GHB IIIs; Tosoh, Tokyo, Japan) with a
reference range of 4.5–6.2%.
Outcomes
The primary outcome was the compari-
son of A1C change and the proportion of
subjectswhoreachedthetreatmenttarget
(A1C7.0or6.5%at6and12months,
respectively). The secondary outcome
was the -cell function and insulin sensi-
Table 1—Baseline demographic and clinical characteristics in the two treatment groups
Insulin group
(intention to treat)
OAD group
(intention to treat)
Insulin group
(A1C 7.0%)
OAD group
(A1C 7.0%)
n 25 19 22 8
Age (years) 57.9  8.5 59.6  12.6 58.7  16.0 56.5  15.9
Sex (male:female) 19:6 13:6 17:5 5:3
Body weight (kg) 71.4  10.6 71.7  21.3 71.2  10.3 71.8  23.6
BMI (kg/m
2) 27.55  4.20 28.31  6.20 27.69  6.58 26.64  8.01
Peak FPG (mg/dl)* 345.0  82.2 329.2  24.0 338.6  66.4 311.3  94.0
Peak plasma glucose (mg/dl)* 527.3  163.8 483.7  217.2 557.4  160.9 487.6  142.1
A1C (%) 11.89  1.91 11.33  1.57 11.73  1.94 11.29  1.46
Systolic blood pressure (mmHg) 125.4  13.4 130.7  12.9 129.2  12.4 130.0  15.7
Diastolic blood pressure (mmHg) 74.2  10.6 78.5  8.1 76.1  10.0 79.7  11.3
Total cholesterol (mg/dl) 193.1  54.8 184.7  39.5 202.3  56.9 197.2  25.0
HDL cholesterol (mg/dl) 45.9  15.1 45.7  12.7 44.4  14.2 45.7  16.0
Triglycerides (mg/dl) 135 (52–1,234) 131 (34–1,074) 135 (52–1,234) 92 (34–794)
Urine albumin-to-creatinine ratio (mg/g) 14.1 (3.2–293.9) 17.3 (4.2–626.2) 15.4 (3.2–293.9) 17.9 (6.7–418.0)
Data are means  SD or means (range). *Peak FPG and plasma glucose indicate the peak glucose level before randomization. The two right columns revealed those
subjects whose A1C level was 7.0%. Since the patients in the OAD group did not achieve the same glycemic target as the insulin group, we therefore only chose
those with A1C level 7% to assess -cell function and insulin resistance.
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glycemic rate, and weight change.
Statistical analyses
The SPSS program for Windows, version
15.0, was used for data analysis. The
paired Student’s t test was used to analyze
the difference from baseline to the end
point, and the independent Student’s t
test was used to compare differences be-
tween the management programs.
ChangesfrombaselineinA1C,meanself-
monitored blood glucose, insulin dose,
OAD dose, body weight, and hypoglyce-
mic events were analyzed using one-way
ANOVA. Data are presented as means 
SD, unless otherwise stated, and a P value
of 0.05 was taken to indicate a signiﬁ-
cant difference.
RESULTS
Study design
Thisstudywasarandomized,open-label,
parallel trial (online appendix ﬁgure
[available at http://dx.doi.org/10.2337/
dc08-0075]). Randomization was per-
formed after 10–14 days of intensive
insulin treatment. Because we suspected
that some patients would refuse insulin
therapy after randomization, we at-
tempted to minimize patient dropout by
randomizinginathree-to-twofashionbe-
tween OADs and insulin. There were 60
patients with type 2 diabetes who were
assessed for eligibility, and 50 subjects
were randomized. Thirty patients were
randomlyassignedtoreceiveinsulinther-
apy and 20 patients to undergo OAD
treatment.
Baseline characteristics
The baseline clinical characteristics and
biochemical status of the patients in the
insulinandOADgroupsareshowninTa-
ble 1. The data presented in Table 1 were
obtainedafter10–14daysofintensivein-
sulin therapy, except for peak fasting and
random plasma glucose levels. The two
treatment groups did not differ signiﬁ-
cantly in baseline clinical features.
Insulin and OAD dosage
During the study period, the insulin dose
was decreased from 26.4  10.5 IU/day
to 16.8  11.0 IU/day. Eleven patients
started with gliclazide-MR and eight with
metformin. The OAD dosage was in-
creased gradually and titrated to 54.5 
22.5 mg/day of gliclazide-MR and 884 
416mg/dayofmetforminattheendofthe
intervention. There were four patients
who only used gliclazide-MR (mean dose
45 mg) and four patients who only used
metformin (mean dose 750 mg), and six
of them reached the target A1C (7.0%).
There were 10 patients who combined
both drugs (mean dose gliclazide-MR 60
mg and metformin 1,200 mg).
Glycemic control
Figure 1A shows the FPG concentration
in both groups in the study period. The
FPG level was stable in the insulin group,
while it increased in week 2 and week 4
and then decreased gradually in the OAD
group.Figure1BrevealstheA1Cchanges
in both groups during the study period
Figure 1—Glycemic control in the insulin treatment group and OAD treatment group. A: FPG
concentration (mean  SE) in both groups in the study period; 2 weeks means prerandomiza-
tion.F,insulingroup;E,OADgroup.B:TheA1Cchanges(meanSE)inbothgroupsduringthe
study period and follow-up visit. F, insulin group; E, OAD group. C: The proportion with A1C
6.5or7.0%at6monthsand1year.*P0.05betweengroups.f,insulingroup; ,OADgroup.
Chen and Associates
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tervention,theA1Clevelwassigniﬁcantly
lower in the insulin group than in the
OAD group (6.33  0.70% vs. 7.50 
1.50%; P  0.002). During the follow-up
visits, the A1C level was still better in the
insulin group (6.78  1.21% vs. 7.84 
1.74%; P  0.009). Figure 1C shows the
proportion with an A1C level 6.5 or
7.0%at6monthsand1year.Thepropor-
tions of patients with A1C levels reaching
these targets at 6 months and 1 year were
signiﬁcantly greater in the insulin group
(P  0.001).
-Cell function and insulin
resistance
Since the patients in the OAD group did
not achieve the same glycemic target as
theinsulingroup,wethereforeonlychose
thosewithA1Clevel7%toassess-cell
functionandinsulinresistance.Therewas
no difference between the two subgroups
of the OAD group at the baseline (online
appendix Table). Table 2 reveals the
changes in biochemical measurements
over the course of the study, and the
plasma glucose and insulin excursions at
each OGTT are illustrated in Fig. 2. All
parameters regarding -cell function
measured in the OGTT were improved
signiﬁcantly in both groups after 6
monthsofintensivetreatment.Compared
withtheOADgroup,theHOMA-index,
insulin AUC, and insulinogenic index
weresigniﬁcantlyimprovedintheinsulin
group.TheHOMA-IRandMatsudaindex
for insulin resistance showed no signiﬁ-
cant change from baseline to the end of
the intervention and without differences
between the two groups.
Adverse events
No severe hypoglycemia occurred in ei-
ther group. The overall rate of minor hy-
poglycemia showed no signiﬁcant
difference between the two groups
(1.39  1.16 vs. 2.30  1.87 episodes;
P  0.082). There was a small increase in
body weight from baseline to the end
point in the insulin group (from 71.4 
10.6 to 73.1  11.6 kg; P  0.028) and
the OAD group (from 71.7  21.3 to
72.518.8kg;P0.021),buttherewas
Figure 2—Mean  SE for plasma glucose (A) and insulin (B) concentration during the OGTT at
baselineand6monthslaterinbothgroups.*P0.05betweengroups;#P0.05baselinevs.after
treatment. F, OAD group, after treatment; E, OAD group, at baseline;  , insulin group, after
treatment; ‚, insulin group, at baseline.
Table 2—Measures of glycemia and insulin secretion during OGTT before and after intensive treatment
Start of study period End of intervention period
Insulin group OAD group Insulin group OAD group
n 22 8 22 8
Sex (male:female) 17:5 5:3 17:5 5:3
A1C (%) 11.73  1.94 11.29  1.46 6.15  0.51* 6.40  0.39*
HOMA-IR 3.81  1.48 4.33  1.42 4.39  2.85 3.95  3.23
HOMA- (%) 49.7  19.7 67.0  31.0 111.2  66.7*† 69.1  33.5
Glucose AUC (mg   h
1   dl
1) 639.1  102.7 586.5  120.8 457.5  87.5* 498.1  107.8*
Insulin AUC (	U   h
1   ml
1) 58.3  18.7 66.1  16.9 158.0  71.9*† 93.04  44.7*
Insulin0–30/Glucose0–30 (	U/mg) 1.30  0.85 1.39  1.22 6.48  5.05*† 2.78  1.78*
Matsuda index 114.9  31.4 108.4  14.2 86.0  25.5 104.3  22.4
InsulinAUC/GlucoseAUC (	U/mg) 1.17  0.71 1.17  0.71 6.52  4.20*† 3.33  2.11*
DataaremeansSD.WeonlychosethosepatientswithA1Clevel7.0%toassess-cellfunctionandinsulinsensitivity.*P0.05vs.baseline;†P0.05between
each group at the end of the study.
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CONCLUSIONS — The study showed
that desired glycemic control was suc-
cessfully achieved by intensive insulin
therapy for 10–14 days in cases of newly
diagnosed type 2 diabetes with severe hy-
perglycemia.However,mostofthesesub-
jects required pharmacological therapy to
maintain near-euglycemia in our study pe-
riod. A 6-month course of further insulin
therapy, compared with OAD treatment,
could more effectively achieve a near-
normal A1C level. We also found that pa-
rameters of the -cell function were better
improved in the insulin-treated than in the
OAD-treated patients.
There has emerged evidence that
short-term intensive insulin therapy in
newly diagnosed type 2 diabetes could
improve glycemic control associated with
improvedinsulinsecretion(5–7).Ryanet
al. (6) recently reported that, in 16 newly
diagnosed type 2 diabetic case subjects
withmoderatehyperglycemia(meanfast-
ing blood glucose of 239 mg/dl), a 2- to
3-week course of intensive insulin ther-
apy was able to maintain good glycemic
control at 1 year in seven of the subjects.
In a similar study (7), 138 newly diag-
nosedtype2diabeticpatientswithfasting
blood glucose 200 mg/dl (mean fasting
blood glucose of 268 mg/dl, peak blood
glucose of 390 mg/dl) were hospitalized
and treated with continuous subcutane-
ous insulin infusion for 2 weeks. Optimal
glycemic control was achieved within
6.3  3.9 days in 126 patients. The re-
mission rate at the 12th month was
47.1%. In patients with moderate hyper-
glycemia,a2-weekcourseofintensivein-
sulin therapy achieving near-euglycemia
mightinducelong-termglycemiccontrol.
This result may not be suitable in patients
with severe hyperglycemia, such as our
subjects with mean initial fasting blood
glucose of 338 mg/dl and peak blood glu-
cose of 508 mg/dl. All of our study sub-
jects had received 10–14 days of
intensive insulin therapy in hospital to
make sure the glycemic control was opti-
mal. After randomization, almost all of
the patients were unable to maintain eu-
glycemia without medication. Our data
revealed that 10–14 days of intensive in-
sulintreatmentwithnear-normoglycemia
cannot maintain good glycemic control
lasting for a long period. We suggest that
short-term intensive insulin therapy may
induce long-term glycemic control in
newly diagnosed type 2 diabetes with
moderate hyperglycemia but not in pa-
tients with severe hyperglycemia. Further
treatment with insulin for at least 1 year
was necessary to maintain the euglycemia
and improve -cell function.
Thefavorableeffectofinsulintreatment
on endogenous insulin secretion in our
study could be due to better glycemic con-
trol. Glucose toxicity has been demon-
strated clinically and has been investigated
extensivelyinthelaboratory(13).Defectsin
insulin secretion have been documented
and directly related to hyperglycemia and
are correctable with the establishment of
euglycemia (14,15). Thus, the shorter the
period of antecedent glucotoxicity, the
more likely the full recovery of -cell func-
tion. Our results do support the concept
that correction of hyperglycemia can im-
prove insulin secretion. Another possibility
is that -cell secretory capacity may have
beenrestoredby“rested”-cellsinducedby
insulin injection (16). In our study, most of
thesubjectsrequiredpharmacologicalther-
apy to maintain near-euglycemia after dis-
continuing insulin therapy. In the insulin-
treated subjects, the fasting blood glucose
levelsweremaintainedbetween90and130
mg/dl,withtheinsulindosedecreasedfrom
26.4 to 16.8 IU per day, which means en-
dogenous insulin secretion was increased.
In the OAD-treated patients, however, the
OADdoseswereuptitratedinthefollowing
6 months to reach our glycemic target. Our
data provide evidence that a short-term in-
tensive insulin therapy can shorten the pe-
riod of glucotoxicity and another 6 months
of insulin therapy can further improve en-
dogenous insulin secretion.
Some reports have shown that induc-
tion of normoglycemia in type 2 diabetes
results in improved insulin resistance
(17–19). In our present study, the insulin
resistance measured by HOMA-IR and
Matsuda index showed no signiﬁcant
change from baseline to the end of the
intervention in both groups and without
signiﬁcant difference between the two
groups. The insulin resistance measured
during the OGTT in our study was per-
formed after intensive insulin therapy for
10–14days.Somedegreeofinsulinresis-
tance might have been corrected in the
10–14 days of intensive insulin therapy.
Both intensive therapy, either with OADs
or insulin, could not further increase in-
sulin sensitivity by improving glycemic
control in the following 6 months. This
should be conﬁrmed by further study.
One limitation of our study is that
some subjects in the OAD group were
treated with different orders of glicla-
zide-MR and metformin. Sulfonylureas
and metformin have different actions on
the insulin sensitivity and secretion in
type2diabeticpatients.Ourtitrationpro-
tocolwasalsoinadequatetofullytreatthe
patients randomized to OADs. It might
have been more effective to use a modern
OAD protocol utilizing self–blood glu-
cose monitoring and more frequent titra-
tion to rapidly achieve a full dose and get
more optimal glycemic control. Further
studies will be required to intensively
treat patients with insulin or one OAD to
achieve the same glycemic control and
then compare the -cell function. An-
otherlimitationisthatthenumbersinthis
study were small and used indirect meth-
ods for assessing -cell function and in-
sulin sensitivity. The results need to
conﬁrm with a larger study and a better
methodologybeforebeingconsideredasa
routine clinical option.
Inconclusion,ourdatademonstrated
that intensive insulin therapy for 10–14
days can achieve optimal glycemic con-
trol in newly diagnosed type 2 diabetes
with severe hyperglycemia but cannot in-
duce a long-term glycemic control. A
6-month course of further insulin ther-
apy, compared with OAD treatment,
could more effectively maintain adequate
glycemic control accompanied with sig-
niﬁcant improvement of -cell function.
Therefore, in the management of newly
diagnosed type 2 diabetic patients with
severe hyperglycemia, strong consider-
ation should be given to early, aggressive
insulin therapy for a rapid and sustained
effect on glycemic control and -cell
function.
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